Picture loading failed.

Pre-Made Tixagevimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Comment: Tixagevimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2 [1]. It was developed by AstraZeneca. This mAb blocks spike binding to ACE2 and prevents infection in animals.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-583-1mg 1mg 3090
GMP-Bios-ab-583-10mg 10mg Inquiry
GMP-Bios-ab-583-100mg 100mg Inquiry
GMP-Bios-ab-583-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Tixagevimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody
INN Name Tixagevimab
TargetSARS-CoV-2 Spike RBD
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommendedna
CompaniesAstraZeneca
Conditions Approvedna
Conditions ActiveCOVID-19
Conditions Discontinuedna
Development Techna